Login to Your Account



Takeda Grabs 'Noro' Contender

LigoCyte Buyout Beats Odds; Viral 'Load' on the Front End

By Nuala Moran and Randy Osborne
Staff Writers

Friday, October 5, 2012
deals_and_ma.jpg

It was an unlikely project, all the way around.

First, getting together a syndicate of venture capital investors to bet on vaccines – medicines typically given to healthy subjects, which makes possible toxicity an especially dicey proposition.

"You cannot have a safety problem, or you're dead," said Ivor Royston, founding managing partner of Forward Ventures, apparently intending no pun. "Why would a venture capitalist invest in something like that?"

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription